Skip to main content
SpringerLink
Log in

Cancer of unknown primary (CUP)

  • Topic_CUP
  • Published:
best practice onkologie Aims and scope

Cancer of unknown primary (CUP; Krebs bei unbekanntem Primärtumor) ist eine onkologische Standarddiagnose mit klarem Diagnostik- und Therapiealgorithmus. Die Diagnostik hat die Etablierung einer Arbeitsdiagnose zum Ziel. Sie stützt sich auf die Klinik sowie bildgebende, histologische und immunhistologische Analysen. Die Therapie sollte nicht durch repetitive Diagnostik verzögert werden. Wichtig ist die Identifikation der ca. 20 % aller CUP-Patienten mit günstiger Prognose und z. T. kurativem Therapieansatz.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

1
2

Literatur

  1. Abbruzzese JL, Abbruzzese MC, Hess KR et al (1994) Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients. J Clin Oncol 12: 1272–1280

    CAS  PubMed  Google Scholar 

  2. Amela EY, Lauridant-Philippin G, Cousin S et al (2012) Management of „unfavourable“ carcinoma of unknown primary site: synthesis of recent literature. Crit Rev Oncol Hematol 84: 213–223

    Article  PubMed  Google Scholar 

  3. Bahrami A, Truong LD, Ro JY (2008) Undifferentiated tumor: true identity by immunohistochemistry. Arch Pathol Lab Med 132: 326–348

    PubMed  Google Scholar 

  4. Culine S (2009) Prognostic factors in unknown primary cancer. Semin Oncol 36: 60–64

    Article  CAS  PubMed  Google Scholar 

  5. Dova L, Pentheroudakis G, Georgiou I et al (2007) Global profiling of EGFR gene mutation, amplification, regulation and tissue protein expression in unknown primary carcinomas: to target or not to target? Clin Exp Metastasis 24: 79–86

    Article  CAS  PubMed  Google Scholar 

  6. Eagan RT, Therneau TM, Rubin J et al (1987) Lack of value for cisplatin added to mitomycin-doxorubicin combination chemotherapy for carcinoma of unknown primary site. A randomized trial. Am J Clin Oncol 10: 82–85

    Article  CAS  PubMed  Google Scholar 

  7. Ettinger DS, Agulnik M, Cates JM et al (2011) Occult primary. J Natl Compr Canc Netw 9: 1358–1395

    PubMed  Google Scholar 

  8. Fizazi K, Greco FA, Pavlidis N et al (2011) Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 22 (Suppl 6): 64–68

    Google Scholar 

  9. French CA, Kutok JL, Faquin WC et al (2004) Midline carcinoma of children and young adults with NUT rearrangement. J Clin Oncol 22: 4135–4139

    Article  CAS  PubMed  Google Scholar 

  10. Goldberg RM, Smith FP, Ueno W et al (1986) 5-fluorouracil, adriamycin, and mitomycin in the treatment of adenocarcinoma of unknown primary. J Clin Oncol 4: 395–399

    CAS  PubMed  Google Scholar 

  11. Golfinopoulos V, Pentheroudakis G, Salanti G et al (2009) Comparative survival with diverse chemotherapy regimens for cancer of unknown primary site: multiple-treatments meta-analysis. Cancer Treat Rev 35: 570–573

    Article  CAS  PubMed  Google Scholar 

  12. Greco FA, Burris HA III, Litchy S et al (2002) Gemcitabine, carboplatin, and paclitaxel for patients with carcinoma of unknown primary site: a Minnie Pearl Cancer Research Network study. J Clin Oncol 20: 1651–1656

    Article  CAS  PubMed  Google Scholar 

  13. Hainsworth JD, Rubin MS, Spigel DR et al (2013) Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon research institute. J Clin Oncol 31: 217–223

    Article  CAS  PubMed  Google Scholar 

  14. Hainsworth JD, Schnabel CA, Erlander MG et al (2012) A retrospective study of treatment outcomes in patients with carcinoma of unknown primary site and a colorectal cancer molecular profile. Clin Colorectal Cancer 11: 112–118

    Article  PubMed  Google Scholar 

  15. Hainsworth JD, Spigel DR, Clark BL et al (2010) Paclitaxel/carboplatin/etoposide versus gemcitabine/irinotecan in the first-line treatment of patients with carcinoma of unknown primary site: a randomized, phase III Sarah Cannon Oncology Research Consortium Trial. Cancer J 16: 70–75

    Article  CAS  PubMed  Google Scholar 

  16. Hainsworth JD, Spigel DR, Farley C et al (2007) Phase II trial of bevacizumab and erlotinib in carcinomas of unknown primary site: the Minnie Pearl Cancer Research Network. J Clin Oncol 25: 1747–1752

    Article  CAS  PubMed  Google Scholar 

  17. Hainsworth JD, Spigel DR, Thompson DS et al (2009) Paclitaxel/carboplatin plus bevacizumab/erlotinib in the first-line treatment of patients with carcinoma of unknown primary site. Oncologist 14: 1189–1197

    Article  PubMed  Google Scholar 

  18. Handorf CR (2011) Gene expression analysis and immunohistochemistry in evaluation of cancer of unknown primary: time for a patient-centered approach. J Natl Compr Cancer Netw 9: 1415–1420

    Google Scholar 

  19. Hemminki K, Ji J, Sundquist J et al (2011) Familial risks in cancer of unknown primary: tracking the primary sites. J Clin Oncol 29: 435–440

    Article  PubMed  Google Scholar 

  20. Hübner G, Wildfang I, Schmoll H-J (2005) Metastasen bei unbekanntem Primärtumor — CUP-Syndrom. In: Schmoll H-J, Höffken K, Possinger K (Hrsg) Kompendium internistische Onkologie. Springer, Berlin Heidelberg New York, S 5317–5365

    Google Scholar 

  21. Hübner G, Link H, Kohne CH et al (2009) Paclitaxel and carboplatin vs gemcitabine and vinorelbine in patients with adeno- or undifferentiated carcinoma of unknown primary: a randomised prospective phase II trial. Br J Cancer 100: 44–49

    Article  Google Scholar 

  22. Keller F, Psychogios G, Linke R et al (2011) Carcinoma of unknown primary in the head and neck: comparison between positron emission tomography (PET) and PET/CT. Head Neck 33: 1569–1575

    Article  PubMed  Google Scholar 

  23. Kwee TC, Kwee RM (2009) Combined FDG-PET/CT for the detection of unknown primary tumors: systematic review and meta-analysis. Eur Radiol 19: 731–744

    Article  PubMed Central  PubMed  Google Scholar 

  24. Milliken ST, Tattersall MH, Woods RL et al (1987) Metastatic adenocarcinoma of unknown primary site. A randomized study of two combination chemotherapy regimens. Eur J Cancer Clin Oncol 23: 1645–1648

    Article  CAS  PubMed  Google Scholar 

  25. Neben K, Hübner G, Folprecht G et al (2008) Metastases in the absence of a primary tumor: advances in the diagnosis and treatment of CUP syndrome. Dtsch Ärztebl Int 105: 733–740

    PubMed Central  PubMed  Google Scholar 

  26. Pavlidis N, Fizazi K (2009) Carcinoma of unknown primary (CUP). Crit Rev Oncol Hematol 69: 271–278

    Article  PubMed  Google Scholar 

  27. Pavlidis N, Pentheroudakis G (2012) Cancer of unknown primary site. Lancet 379: 1428–1435

    Article  PubMed  Google Scholar 

  28. Pavlidis N, Pentheroudakis G, Plataniotis G (2009) Cervical lymph node metastases of squamous cell carcinoma from an unknown primary site: a favourable prognosis subset of patients with CUP. Clin Transl Oncol 11: 340–348

    Article  PubMed  Google Scholar 

  29. Pentheroudakis G, Golfinopoulos V, Pavlidis N (2007) Switching benchmarks in cancer of unknown primary: from autopsy to microarray. Eur J Cancer 43: 2026–2036

    Article  PubMed  Google Scholar 

  30. Pentheroudakis G, Pavlidis N (2010) Serous papillary peritoneal carcinoma: unknown primary tumour, ovarian cancer counterpart or a distinct entity? A systematic review. Crit Rev Oncol Hematol 69: 271–278

    Google Scholar 

  31. Seve P, Billotey C, Broussolle C et al (2007) The role of 2-deoxy-2-[F-18]fluoro- D-glucose positron emission tomography in disseminated carcinoma of unknown primary site. Cancer 109: 292–299

    Article  PubMed  Google Scholar 

  32. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62: 10–29

    Article  PubMed  Google Scholar 

  33. Strojan P, Ferlito A, Langendijk JA et al (2013) Contemporary management of lymph node metastases from an unknown primary to the neck: II. a review of therapeutic options. Head Neck 35: 286–293

    Article  PubMed  Google Scholar 

  34. Woods RL, Fox RM, Tattersall MH et al (1980) Metastatic adenocarcinomas of unknown primary site: a randomized study of two combinationchemotherapy regimens. N Engl J Med 303: 87–89

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Onkologie und Hämatologie, Universitätsklinikum Halle, Martin-Luther-Universität Halle-Wittenberg, Ernst-Grube-Str. 40, 06114, Halle (Saale), Deutschland

    T. Weber & H. -J. Schmoll

  2. Zentrum für Innere Medizin, Sana Kliniken Ostholstein, Klinik Oldenburg, Oldenburg, Deutschland

    G. Hübner

  3. Gemeinschaftspraxis für Strahlentherapie und Radioonkologie, Hannover, Deutschland

    I. Wildfang

Authors
  1. T. Weber
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. -J. Schmoll
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G. Hübner
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. I. Wildfang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T. Weber.

Additional information

Einhaltung ethischer Richtlinien

Interessenkonflikt. T. Weber, G. Hübner, I. Wildfang und H.-J. Schmoll geben an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine Studien an Menschen oder Tieren.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Weber, T., Schmoll, H.J., Hübner, G. et al. Cancer of unknown primary (CUP). best practice onkologie 9, 22–30 (2014). https://doi.org/10.1007/s11654-013-0116-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11654-013-0116-3

Search

Navigation